Welcome to MedsFacts the next generation reference for medication safety. With more than 70% of all Americans currently taking at least one prescription drug – and at least 50% of all Americans taking two or more medications – it’s more critical than ever that we are informed, engaged and aware of potential side effects and adverse reactions.

MedsFacts is the premiere destination for the latest prescription drug and healthcare news. MedsFacts analyzes more than 18 million FDA adverse drug reports for 20,000 different pharmaceutical products, enabling patients and providers to better understand the potential side effects of different medications, along with potentially harmful interactions. Our easy-to-use online tools help you quickly assess the benefits and potential dangers associated with different medications. These easy-to-use diagnostic tools empower you to take charge of your health!

In conjunction with our redesigned website launch, the MedsFacts team is excited to announce our newest feature: the ability to consult with expert physicians and scientific researchers about different prescription medications. Patients can ask questions about their medications, providers can post responses to patient concerns, and patients can also schedule a personal consultation with a medication expert – all from within the MedsFacts website.

Using our community forum, you can share your own experience with different medications. Did you find that the side effects for a specific drug did not seem to apply to you? Or maybe you experienced other difficulties while taking a specific medication. Share your experiences and interact with other patients who are also taking similar medications for similar health concerns.

As a registered MedsFacts user, you can privately and securely save your medication list to the cloud. Once you’ve saved your medication list, you can receive regular updates from other patients posting questions or concerns about the same medications on your watch list. You control your communication preferences so you only receive the updates that are most relevant to your health concerns.

Wondering whether it is safe to take two medications together? Confused about your medical provider’s prescriptions? Curious if others are experiencing the same side effects as you? Sign up for MedsFacts today. Joining MedsFacts is completely free and will give you access to all our easy-to-use tools, including expert physician and researcher consultations and our community forums. You’ll be able to view user comments and concerns, and interact with patients who take similar medications.

Stay informed and take control of your health: click here to join the growing MedsFacts community.

 

About this MedsFacts analysis covering adverse side effect reports of TEBETANE COMPUESTO patients who developed EXTRAPYRAMIDAL DISORDER.

MedsFacts provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and MedsFacts user submissions. Between January 2004 and October 2012, 1 individuals taking TEBETANE COMPUESTO reported EXTRAPYRAMIDAL DISORDER to the FDA. A total of 13 TEBETANE COMPUESTO drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between TEBETANE COMPUESTO and EXTRAPYRAMIDAL DISORDER. In doing so, we compare TEBETANE COMPUESTO with other drugs that cause EXTRAPYRAMIDAL DISORDER, to help you evaluate whether or not TEBETANE COMPUESTO causes EXTRAPYRAMIDAL DISORDER. Likewise, this page shows the most highly-reported side effects of TEBETANE COMPUESTO, so you can see if EXTRAPYRAMIDAL DISORDER ranks among TEBETANE COMPUESTO's most well-known side effects.
Summary Statistics
Reports of TEBETANE COMPUESTO causing EXTRAPYRAMIDAL DISORDER: 1
Reports of any side effect of TEBETANE COMPUESTO : 13
Percentage of TEBETANE COMPUESTO patients where EXTRAPYRAMIDAL DISORDER is a reported side effect: 7.6923%

FDA reports of any drug causing EXTRAPYRAMIDAL DISORDER : 18150
Average percentage for all medicated patients where EXTRAPYRAMIDAL DISORDER is reported as a complication: 0.1138%

Physician opinion on TEBETANE COMPUESTO as adverse event culprit:

Overall opinion for all reports of this drug:
Most frequent diagnoses/indications for prescribing TEBETANE COMPUESTO:
PROSTATISM ( 4 patients )
BENIGN PROSTATIC HYPERPLASIA ( 2 patients )
DRUG USE FOR UNKNOWN INDICATION ( 1 patients )
( 0 patients )
Drugs with high FDA adverse event association with EXTRAPYRAMIDAL DISORDER:

METOCLOPRAMIDE (19661 patients)
REGLAN (4979 patients)
RISPERDAL (925 patients)
SEROQUEL (649 patients)
METOCLOPRAMIDE HYDROCHLORIDE (644 patients)
HALOPERIDOL (619 patients)
ABILIFY (453 patients)
RISPERIDONE (416 patients)
ZYPREXA (390 patients)
GEODON (285 patients)
RISPERDAL CONSTA (283 patients)
HALDOL (274 patients)
LORAZEPAM (246 patients)
INVEGA (234 patients)
ASPIRIN (228 patients)
OLANZAPINE (196 patients)
NEXIUM (185 patients)
OMEPRAZOLE (162 patients)
DEPAKOTE (158 patients)
CLOZAPINE (157 patients)
ZOLOFT (154 patients)
CITALOPRAM HYDROBROMIDE (148 patients)
CLONAZEPAM (146 patients)
LITHIUM CARBONATE (145 patients)
DIAZEPAM (143 patients)
PAXIL (138 patients)
PROZAC (135 patients)
NEURONTIN (134 patients)
ALPRAZOLAM (134 patients)
XANAX (118 patients)
LISINOPRIL (112 patients)
LAMICTAL (110 patients)
EFFEXOR (107 patients)
PROTONIX (106 patients)
PRILOSEC (106 patients)
CLOZARIL (105 patients)
LIPITOR (105 patients)
LEXAPRO (104 patients)
FUROSEMIDE (103 patients)
HALOPERIDOL DECANOATE (102 patients)
COGENTIN (101 patients)
VALPROATE SODIUM (101 patients)
MIRTAZAPINE (100 patients)
GABAPENTIN (99 patients)
CYMBALTA (99 patients)
LYRICA (99 patients)
PREV MEDS (98 patients)
SIMVASTATIN (98 patients)
PROMETHAZINE (98 patients)
HYDROCHLOROTHIAZIDE (94 patients)
INVEGA SUSTENNA (93 patients)
ARICEPT (93 patients)
TRAZODONE HCL (92 patients)
CON MEDS (90 patients)
ACETAMINOPHEN (90 patients)
PLAVIX (89 patients)
ATIVAN (89 patients)
NITROGLYCERIN (88 patients)
BENADRYL (87 patients)
DEPAKENE (87 patients)
METOCLOPRAMIDE TABLETS USP, 10 MG (PUREPAC) (87 patients)
FLUOXETINE (86 patients)
VIOXX (86 patients)
LASIX (84 patients)
PREVACID (83 patients)
METOCLOPRAMIDE HCL (83 patients)
ALBUTEROL (81 patients)
AMBIEN (81 patients)
LEVAQUIN (80 patients)
ARIPIPRAZOLE (80 patients)
ESCITALOPRAM (80 patients)
LEVOTHYROXINE SODIUM (79 patients)
PREDNISONE (79 patients)
WELLBUTRIN (78 patients)
CELEXA (77 patients)
AMITRIPTYLINE HCL (74 patients)
KLONOPIN (74 patients)
CELEBREX (73 patients)
AMOXICILLIN (72 patients)
ZOCOR (71 patients)
FOLIC ACID (71 patients)
VALIUM (71 patients)
QUETIAPINE (71 patients)
CLONIDINE (70 patients)
ZOFRAN (70 patients)
QUETIAPINE FUMARATE (70 patients)
ZOLPIDEM (69 patients)
TRAMADOL HCL (69 patients)
IBUPROFEN (66 patients)
LEPONEX (66 patients)
SAPHRIS (66 patients)
METFORMIN HCL (66 patients)
AMLODIPINE (64 patients)
HYDROCODONE BITARTRATE AND ACETAMINOPHEN (64 patients)
INSULIN (64 patients)
ACE INHIBITORS (63 patients)
ATENOLOL (63 patients)
MIRAPEX (63 patients)
SINGULAIR (62 patients)
LIPID LOWERING THERAPY (62 patients)
POTASSIUM CHLORIDE (62 patients)
LANTUS (62 patients)
PAROXETINE HCL (62 patients)
OXYCODONE HCL (61 patients)
CEPHALEXIN (61 patients)
LITHIUM (60 patients)
NORVASC (60 patients)
VICODIN (59 patients)
ZITHROMAX (59 patients)
SERTRALINE HYDROCHLORIDE (57 patients)
AKINETON (57 patients)
LAMOTRIGINE (57 patients)
CIPROFLOXACIN (57 patients)
ZANTAC (57 patients)
TOPAMAX (56 patients)
EXELON (54 patients)
TOPROL-XL (54 patients)
METOPROLOL TARTRATE (54 patients)
SINEMET (54 patients)
TEMAZEPAM (53 patients)
PREMARIN (53 patients)
OXAZEPAM (51 patients)
BIPERIDEN HYDROCHLORIDE TAB (51 patients)
FOSAMAX (50 patients)
TERCIAN (49 patients)
BACLOFEN (49 patients)
COUMADIN (49 patients)
PROPRANOLOL (48 patients)
ATARAX (48 patients)
REQUIP (47 patients)
CLINDAMYCIN (47 patients)
VALPROIC ACID (46 patients)
TEGRETOL (46 patients)
RIVOTRIL (46 patients)
REMERON (45 patients)
FLEXERIL (45 patients)
AMISULPRIDE (45 patients)
RANITIDINE (44 patients)
ZYRTEC (44 patients)
OXYCONTIN (44 patients)
PROCYCLIDINE HYDROCHLORIDE 2MG TAB (43 patients)
ORAL HYPOGLYCAEMICS (42 patients)
FAMOTIDINE (42 patients)
SYNTHROID (42 patients)
DARVOCET (42 patients)
ELAVIL (41 patients)
EFFEXOR XR (41 patients)
PANTOPRAZOLE (41 patients)
CRESTOR (41 patients)
FERROUS SULFATE TAB (40 patients)
FLUCONAZOLE (40 patients)
NOZINAN (40 patients)
PREDNISOLONE (40 patients)
MECLIZINE (40 patients)
SEROQUEL XR (39 patients)
IMOVANE (39 patients)
BENZTROPINE MESYLATE (39 patients)
PERCOCET (38 patients)
CORDARONE (38 patients)
VITAMIN D (38 patients)
ALLOPURINOL (38 patients)
ONDANSETRON (37 patients)
AUGMENTIN '125' (37 patients)
MORPHINE (36 patients)
PALIPERIDONE (36 patients)
FENTANYL (36 patients)
PAROXETINE (36 patients)
VITAMIN B-12 (36 patients)
FLOMAX (36 patients)
NAPROXEN (35 patients)
DEROXAT (35 patients)
KEPPRA (35 patients)
TEMESTA (35 patients)
MEMANTINE HCL (35 patients)
CITALOPRAM (35 patients)
FLONASE (35 patients)
SOLIAN (35 patients)
CONCERTA (34 patients)
DIGOXIN (34 patients)
HYDROCODONE (34 patients)
ENALAPRIL MALEATE (34 patients)
ACIPHEX (34 patients)
ADVAIR DISKUS 100/50 (34 patients)
AZITHROMYCIN (34 patients)
DIPHENHYDRAMINE HCL (34 patients)
LEPTICUR (33 patients)
KLOR-CON (33 patients)
CARBAMAZEPINE (33 patients)
THORAZINE (33 patients)
ERGENYL (33 patients)
COLACE (33 patients)
NYSTATIN (33 patients)
LANSOPRAZOLE (33 patients)
MIRALAX (33 patients)
GLUCOPHAGE (32 patients)
LOVENOX (32 patients)
RITALIN (32 patients)
PREDNISONE TAB (31 patients)
MOTRIN (31 patients)
METRONIDAZOLE (31 patients)
MULTI-VITAMIN (31 patients)
LORTAB (31 patients)
ZOLPIDEM TARTRATE (31 patients)
NASONEX (31 patients)
COZAAR (30 patients)
ULTRAM (30 patients)
VITAMIN E (30 patients)
CYCLOBENZAPRINE (30 patients)
ERYTHROMYCIN (29 patients)
MUCINEX (29 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the MedsFacts community - currently one million members and growing! MedsFacts online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.


Recent MedsFacts Activity for TEBETANE COMPUESTO


Issue Description / Topic Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited MedsFacts. If you have a question about EXTRAPYRAMIDAL DISORDER and TEBETANE COMPUESTO, post it here. You may receive a response from a fellow patient - or a leading expert in the field.
Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited MedsFacts. If you have a noteworthy experience as a patient taking TEBETANE COMPUESTO, post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.
Your Experience or Concern:

Telemedicine Expert Consults MedsFacts newest feature allows patients to consult - via realtime videoconferencing - experts in TEBETANE COMPUESTO. This premium feature connects patients to experts, regardless of geography. MedsFacts experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.
We are currently accepting registration for TEBETANE COMPUESTO experts. If you are a healthcare provider experienced in prescribing TEBETANE COMPUESTO, please register here.
© 2014 MedsFacts, Inc
Privacy Policy
Terms of Use